Cite
HARVARD Citation
Spicer, J. et al. (n.d.). Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. European journal of cancer. 51 (2), pp. 137-145. [Online].